Optina develops a Retinal Deep Phenotyping platform that leverages retinal imaging and AI to assess brain health and systemic disease, including a cerebral amyloid status test (awAIrTM) for Alzheimer’s detection. The company holds FDA Breakthrough Device Designation for its first indication (2019) and received 501(k) clearance for its Optina-4CTM hyperspectral camera in 2020. Optina is advancing a pivotal clinical study for FDA regulatory submission of the awAIrTM test and plans to expand the study cohort across five sites in the U.S., Canada and Europe. Recent financing will support enlargement of that pivotal cohort and alignment of the platform with novel therapeutic approvals. The company is led by CEO David Lapointe and is based in Montreal, Canada. Optina previously closed a Series A led by DigitalDx Ventures with participation from Boehringer Ingelheim Venture Fund, Desjardins, Zoic Capital and others. Optina Diagnostics develops a Retinal Deep Phenotyping™ platform that uses non‑invasive retinal imaging and AI to support diagnosis and management of brain health (including Alzheimer’s) and systemic diseases. Its platform received FDA Breakthrough Device Designation in 2019 for a non‑invasive test to improve Alzheimer’s evaluation. The company is advancing an awAIr™ cerebral amyloid status test and plans a pivotal study to support that indication. Optina intends to use recent funding to further platform development for early detection of systemic diseases and to expand clinical deployments. Management is pursuing installation of its platform at leading clinical sites across the United States, Canada, and Europe. The company recently closed a material Series A financing to fund those studies and deployments.

Total raised

$22M

Funding rounds

2

Latest round

Equity

Latest activity

Jan 2022